Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.40 |
| ▸ | HTR2C | P28335 | 8/20 | 0.40 |
| ▸ | HTR2B | P41595 | 8/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13688252 | 1.00 | HTR2A (0.40) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| SCHEMBL5132477 | 1.00 | HTR2A (0.40) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| SCHEMBL13688249 | 0.83 | HTR2C (0.40) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| SCHEMBL3863376 | 0.83 | HTR2C (0.40) | HTR2AHTR2CHTR2BSLC6A2SLC6A4 | |
| SCHEMBL3860709 | 0.82 | HTR1A (0.40) | HTR2AHTR2CHTR2B | |
| SCHEMBL3856531 | 0.82 | HTR1A (0.40) | HTR2AHTR2CHTR2B | |
| SCHEMBL3860706 | 0.82 | HTR1A (0.40) | HTR2AHTR2CHTR2B | |
| SCHEMBL3856535 | 0.82 | HTR1A (0.40) | HTR2AHTR2CHTR2B | |
| SCHEMBL3856526 | 0.82 | HTR1A (0.40) | HTR2AHTR2CHTR2B | |
| SCHEMBL1844188 | 0.81 | HTR2C (0.48) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581221-B1 | SUBSTITUTED TRICYCLIC GAMMA-CARBOLINES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2011-05-18 | — | — | EP | disclosed |
| US-7592454-B2 | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-22 | — | — | US | disclosed |
| US-7109339-B2 | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050239768-A1 | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2005-10-27 | — | — | US | disclosed |
| US-20040180875-A1 | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180875-A1 | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists | HTR1A, HTR7, HTR5A | HTR2A 13/4885HTR2C 4/4885HTR2B 7/4885 |
| US-20050239768-A1 | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists | HTR1A, HTR7, HTR1D | HTR2A 16/4885HTR2C 18/4885HTR2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.